Document is current
Any future updates will be listed below
-
Authors
Alsugair, Ali
Gauto Mariotti, Estefania https://orcid.org/0000-0001-5710-4714
Alhousani, Mohammad M. https://orcid.org/0000-0002-4345-8770
Fathima, Saubia https://orcid.org/0000-0002-9979-7923
Yousuf, Muhammad
Bolarinwa, Abiola https://orcid.org/0000-0001-5812-1954
Foran, James https://orcid.org/0000-0003-1673-1708
Mangaonkar, Abishek A. https://orcid.org/0000-0003-2458-9887
Litzow, Mark https://orcid.org/0000-0002-9816-6302
Murthy, Hemant
Sproat, Lisa
Palmer, Jeanne
Matin, Aasiya
Ayala, Ernesto
Slack, James
Porrata, Luis
Iqbal, Madiha https://orcid.org/0000-0001-6752-5440
Khera, Nandita
Punwani, Nathan
Kenderian, Saad https://orcid.org/0000-0003-2767-3830
Chhabra, Saurabh https://orcid.org/0000-0001-9117-8696
Hogan, William J. https://orcid.org/0000-0002-5841-4105
Shah, Mithun Vinod https://orcid.org/0000-0002-5359-336X
Alkhateeb, Hassan B.
Gangat, Naseema https://orcid.org/0000-0002-9104-6172
Patnaik, Mrinal https://orcid.org/0000-0001-6998-662X
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
- License Information
-
More Information
Article History
Received: 26 May 2025
Revised: 25 July 2025
Accepted: 28 August 2025
First Online: 6 October 2025
Competing interests
: MVS: Research funding to the institution from AbbVie, Astellas, Celgene, KURA Oncology, and Marker Therapeutics. AT is a co-editor of BCJ but was not involved in either the review or the decision process of the current paper.
: This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number:12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.
